当前位置: 首页 >> 检索结果
64. Quantitation of faecal Fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia.
作者: Sunny H Wong.;Thomas N Y Kwong.;Tai-Cheong Chow.;Arthur K C Luk.;Rudin Z W Dai.;Geicho Nakatsu.;Thomas Y T Lam.;Lin Zhang.;Justin C Y Wu.;Francis K L Chan.;Simon S M Ng.;Martin C S Wong.;Siew C Ng.;William K K Wu.;Jun Yu.;Joseph J Y Sung.
来源: Gut. 2017年66卷8期1441-1448页
There is a need for an improved biomarker for colorectal cancer (CRC) and advanced adenoma. We evaluated faecal microbial markers for clinical use in detecting CRC and advanced adenoma.
66. Leucocyte telomere length, genetic variants at the TERT gene region and risk of pancreatic cancer.
作者: Ying Bao.;Jennifer Prescott.;Chen Yuan.;Mingfeng Zhang.;Peter Kraft.;Ana Babic.;Vicente Morales-Oyarvide.;Zhi Rong Qian.;Julie E Buring.;Barbara B Cochrane.;J Michael Gaziano.;Edward L Giovannucci.;JoAnn E Manson.;Kimmie Ng.;Shuji Ogino.;Thomas E Rohan.;Howard D Sesso.;Meir J Stampfer.;Charles S Fuchs.;Immaculata De Vivo.;Laufey T Amundadottir.;Brian M Wolpin.
来源: Gut. 2017年66卷6期1116-1122页
Telomere shortening occurs as an early event in pancreatic tumorigenesis, and genetic variants at the telomerase reverse transcriptase (TERT) gene region have been associated with pancreatic cancer risk. However, it is unknown whether prediagnostic leucocyte telomere length is associated with subsequent risk of pancreatic cancer.
67. Induction of humoural and cellular immunity by immunisation with HCV particle vaccine in a non-human primate model.
作者: Hiroshi Yokokawa.;Atsunori Higashino.;Saori Suzuki.;Masaki Moriyama.;Noriko Nakamura.;Tomohiko Suzuki.;Ryosuke Suzuki.;Koji Ishii.;Kouji Kobiyama.;Ken J Ishii.;Takaji Wakita.;Hirofumi Akari.;Takanobu Kato.
来源: Gut. 2018年67卷2期372-379页
Although HCV is a major cause of chronic liver disease worldwide, there is currently no prophylactic vaccine for this virus. Thus, the development of an HCV vaccine that can induce both humoural and cellular immunity is urgently needed. To create an effective HCV vaccine, we evaluated neutralising antibody induction and cellular immune responses following the immunisation of a non-human primate model with cell culture-generated HCV (HCVcc).
68. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
作者: Thomas A Mace.;Reena Shakya.;Jason R Pitarresi.;Benjamin Swanson.;Christopher W McQuinn.;Shannon Loftus.;Emily Nordquist.;Zobeida Cruz-Monserrate.;Lianbo Yu.;Gregory Young.;Xiaoling Zhong.;Teresa A Zimmers.;Michael C Ostrowski.;Thomas Ludwig.;Mark Bloomston.;Tanios Bekaii-Saab.;Gregory B Lesinski.
来源: Gut. 2018年67卷2期320-332页
Limited efficacy of immune checkpoint inhibitors in pancreatic ductal adenocarcinoma (PDAC) has prompted investigation into combination therapy. We hypothesised that interleukin 6 (IL-6) blockade would modulate immunological features of PDAC and enhance the efficacy of anti-programmed death-1-ligand 1 (PD-L1) checkpoint inhibitor therapy.
69. High hospital research participation and improved colorectal cancer survival outcomes: a population-based study.
作者: Amy Downing.;Eva Ja Morris.;Neil Corrigan.;David Sebag-Montefiore.;Paul J Finan.;James D Thomas.;Michael Chapman.;Russell Hamilton.;Helen Campbell.;David Cameron.;Richard Kaplan.;Mahesh Parmar.;Richard Stephens.;Matt Seymour.;Walter Gregory.;Peter Selby.
来源: Gut. 2017年66卷1期89-96页
In 2001, the National Institute for Health Research Cancer Research Network (NCRN) was established, leading to a rapid increase in clinical research activity across the English NHS. Using colorectal cancer (CRC) as an example, we test the hypothesis that high, sustained hospital-level participation in interventional clinical trials improves outcomes for all patients with CRC managed in those research-intensive hospitals.
70. The influence of procedural volume and proficiency gain on mortality from upper GI endoscopic mucosal resection.
作者: Sheraz R Markar.;Hugh Mackenzie.;Melody Ni.;Jeremy R Huddy.;Alan Askari.;Omar Faiz.;S Michael Griffin.;Laurence Lovat.;George B Hanna.
来源: Gut. 2018年67卷1期79-85页
Endoscopic mucosal resection (EMR) is established for the management of benign and early malignant upper GI disease. The aim of this observational study was to establish the effect of endoscopist procedural volume on mortality.
71. Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.
作者: Kazumoto Murata.;Mai Asano.;Akihiro Matsumoto.;Masaya Sugiyama.;Nao Nishida.;Eiji Tanaka.;Taisuke Inoue.;Minoru Sakamoto.;Nobuyuki Enomoto.;Takayoshi Shirasaki.;Masao Honda.;Shuichi Kaneko.;Hiroyuki Gatanaga.;Shinichi Oka.;Yuki I Kawamura.;Taeko Dohi.;Yasutaka Shuno.;Hideaki Yano.;Masashi Mizokami.
来源: Gut. 2018年67卷2期362-371页
The clinical significance of polymorphisms in the interleukin-28B gene encoding interferon (IFN)-λ3, which has antiviral effects, is known in chronic HCV but not in HBV infection. Thus, we measured IFN-λ3 levels in patients with HBV and investigated its clinical significance and association with nucleos(t)ide (NUC) analogue administration.
72. An evidence-based treatment algorithm for colorectal polyp cancers: results from the Scottish Screen-detected Polyp Cancer Study (SSPoCS).
作者: C H Richards.;N T Ventham.;D Mansouri.;M Wilson.;G Ramsay.;C D Mackay.;C N Parnaby.;D Smith.;J On.;D Speake.;G McFarlane.;Y N Neo.;E Aitken.;C Forrest.;K Knight.;A McKay.;H Nair.;C Mulholland.;J H Robertson.;F A Carey.;Rjc Steele.; .
来源: Gut. 2018年67卷2期299-306页
Colorectal polyp cancers present clinicians with a treatment dilemma. Decisions regarding whether to offer segmental resection or endoscopic surveillance are often taken without reference to good quality evidence. The aim of this study was to develop a treatment algorithm for patients with screen-detected polyp cancers.
73. All-cause and cancer-specific mortality in GORD in a population-based cohort study (the HUNT study).
作者: Eivind Ness-Jensen.;Eivind Gottlieb-Vedi.;Karl Wahlin.;Jesper Lagergren.
来源: Gut. 2018年67卷2期209-215页
Gastro-oesophageal reflux is a public health concern which could have associated oesophageal complications, including adenocarcinoma, and possibly also head-and-neck and lung cancers. The aim of this study was to test the hypothesis that reflux increases all-cause and cancer-specific mortalities in an unselected cohort.
76. Development of an index to define overall disease severity in IBD.
作者: Corey A Siegel.;Cynthia B Whitman.;Brennan M R Spiegel.;Brian Feagan.;Bruce Sands.;Edward V Loftus.;Remo Panaccione.;Geert D'Haens.;Charles N Bernstein.;Richard Gearry.;Siew C Ng.;Gerassimos J Mantzaris.;Balfour Sartor.;Mark S Silverberg.;Robert Riddell.;Ioannis E Koutroubakis.;Colm O'Morain.;Peter L Lakatos.;Dermot P B McGovern.;Jonas Halfvarson.;Walter Reinisch.;Gerhard Rogler.;Wolfgang Kruis.;Curt Tysk.;Stefan Schreiber.;Silvio Danese.;William Sandborn.;Anne Griffiths.;Bjorn Moum.;Christoph Gasche.;Francesco Pallone.;Simon Travis.;Julian Panes.;Jean-Frederic Colombel.;Stephen Hanauer.;Laurent Peyrin-Biroulet.
来源: Gut. 2018年67卷2期244-254页
Disease activity for Crohn's disease (CD) and UC is typically defined based on symptoms at a moment in time, and ignores the long-term burden of disease. The aims of this study were to select the attributes determining overall disease severity, to rank the importance of and to score these individual attributes for both CD and UC.
79. Uncoupling of mucosal gene regulation, mRNA splicing and adherent microbiota signatures in inflammatory bowel disease.
作者: Robert Häsler.;Raheleh Sheibani-Tezerji.;Anupam Sinha.;Matthias Barann.;Ateequr Rehman.;Daniela Esser.;Konrad Aden.;Carolin Knecht.;Berenice Brandt.;Susanna Nikolaus.;Sascha Schäuble.;Christoph Kaleta.;Andre Franke.;Christoph Fretter.;Werner Müller.;Marc-Thorsten Hütt.;Michael Krawczak.;Stefan Schreiber.;Philip Rosenstiel.
来源: Gut. 2017年66卷12期2087-2097页
An inadequate host response to the intestinal microbiota likely contributes to the manifestation and progression of human inflammatory bowel disease (IBD). However, molecular approaches to unravelling the nature of the defective crosstalk and its consequences for intestinal metabolic and immunological networks are lacking. We assessed the mucosal transcript levels, splicing architecture and mucosa-attached microbial communities of patients with IBD to obtain a comprehensive view of the underlying, hitherto poorly characterised interactions, and how these are altered in IBD.
80. Hypoxia-inducible factor-2α plays a role in mediating oesophagitis in GORD.
作者: Xiaofang Huo.;Agoston T Agoston.;Kerry B Dunbar.;Daisha J Cipher.;Xi Zhang.;Chunhua Yu.;Edaire Cheng.;Qiuyang Zhang.;Thai H Pham.;Uttam K Tambar.;Richard K Bruick.;David H Wang.;Robert D Odze.;Stuart J Spechler.;Rhonda F Souza.
来源: Gut. 2017年66卷9期1542-1554页
In an earlier study wherein we induced acute reflux by interrupting proton pump inhibitor (PPI) therapy in patients with reflux oesophagitis (RO) healed by PPIs, we refuted the traditional concept that RO develops as an acid burn. The present study explored our alternative hypothesis that RO results from reflux-stimulated production of pro-inflammatory molecules mediated by hypoxia-inducible factors (HIFs).
|